TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12207629
Drug: Nebulizer with
Normalized name: AeroNeb Go Nebulizer with Cable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer with 25 g oral charcoal (NEBC)
Study: 12207629
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler (MDI) vs Oral (ORAL)
Study: 12207629
Drug: Nebulizer (NEB)
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer (NEB) vs Oral (ORAL)
Study: 7476326
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg/d for 12 months
Study: 23890351
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg monacolins
Study: 21291335
Drug: Miglitol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (50 mg) before meals
Study: 21291335
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg) before meals
Study: 9404766
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg nebulized 2% lidocaine
Study: 9404766
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg nebulized 2% lidocaine
Study: 3066965
Drug: Hypothiazide 25
Normalized name: CYCLOTHIAZIDE
DrugBank: Cyclothiazide (DB00606)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypothiazide 25 mg
Study: 3066965
Drug: Hypothiazide 50
Normalized name: CYCLOTHIAZIDE
DrugBank: Cyclothiazide (DB00606)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypothiazide 50 mg
Study: 3066965
Drug: Hypothiazide 100
Normalized name: CYCLOTHIAZIDE
DrugBank: Cyclothiazide (DB00606)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypothiazide 100 mg
Study: 3066965
Drug: Oxodoline 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxodoline 50 mg
Study: 3066965
Drug: Oxodoline 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxodoline 100 mg
Study: 25618800
Drug: Curcuminoid-piperine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoid-piperine combination (1 g curcuminoids + 10 mg piperine daily)
Study: 25618800
Drug: Curcuminoid-piperine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoid-piperine combination
Study: 20513160
Drug: LCD 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCD 15% solution (Psorent)
Study: 20513160
Drug: Calcipotriene 0.005%
Normalized name: CALCIPOTRIENE 0.005% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriene 0.005% cream (Dovonex)
Study: 18226128
Drug: Extra-amniotic saline
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic saline solution infusion (EASI) plus dexamethasone 20 mg
Study: 18226128
Drug: Extra-amniotic saline
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic saline solution infusion (EASI) alone
Study: 16967629
Drug: E2/norgestimate (NGM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/norgestimate (NGM) 1 mg/90 microg
Study: 9011450
Drug: Orlistat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (200 mg)
Study: 1334255
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral tetravalent human‐rhesus rotavirus reassortant vaccine
Study: 29321218
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline administration
Study: 25298578
Drug: Lafutidine 10
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine 10 mg once daily for 8 weeks
Study: 25298578
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily for 8 weeks
Study: 15127186
Drug: 4% modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% modified fluid gelatine (GEL)
Study: 11899903
Drug: SRL172 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL172 with chemotherapy (n=14)
Study: 11899903
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (n=14)
Study: 11899903
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment regimens (SRL172 + chemotherapy and chemotherapy alone)
Study: 11899903
Drug: SRL172 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL172 with chemotherapy
Study: 2678635
Drug: Verapamil (VP)
Normalized name: VP-14637
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (VP) therapy prior to administration of CsA
Study: 2678635
Drug: Verapamil (VP)
Normalized name: VP-14637
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (VP) therapy
Study: 31479196
Drug: Myjet-assisted transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myjet-assisted transdermal injection of tranexamic acid (TA)
Study: 31479196
Drug: Myjet-assisted transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myjet-assisted transdermal injection of vitamin C (VC)
Study: 26301771
Drug: brexpiprazole 3
Normalized name: brexpiprazole 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole 3 mg
Study: 23735680
Drug: DEN1Δ30 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEN1Δ30 at 10PFU and 1000PFU doses
Study: 23735680
Drug: DEN2/4Δ30 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEN2/4Δ30 at 10PFU and 1000PFU doses
Study: 23735680
Drug: DEN3Δ30/31 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEN3Δ30/31 at 10PFU and 1000PFU doses
Study: 23735680
Drug: DEN1Δ30 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEN1Δ30 at 1000PFU and 10PFU doses
Study: 21183518
Drug: Intracameral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral lidocaine 1% (0.5 cc)
Study: 19877967
Drug: Benznidazole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole (5 mg/kg per day for 30 days)
Study: 12956652
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine spray applied twice daily
Study: 12956652
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine spray applied once daily plus placebo spray once daily
Study: 1559584
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg (150 mg if B.W. < 40 kg) as a single evening dose for four weeks
Study: 25151658
Drug: Mometasone nasal
Normalized name: mometasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone nasal spray for six months
Study: 25151658
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal spray for six months
Study: 19851798
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) isomers (3.9 g per day, 50:50 t9c11:c10t12)
Study: 19851798
Drug: Placebo (high-oleic-acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (high-oleic-acid sunflower oil, 3.9 g per day)
Study: 12384357
Drug: Ertapenem (INVANZ)
Normalized name: ertapenem Injection [Invanz]
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertapenem (INVANZ) at doses up to 3 g
Study: 10103305
Drug: GM‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF (10 microg/kg/d) by subcutaneous injection for 5 days
Study: 10103305
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GM‐CSF treatment)
Study: 7577779
Drug: Fentanyl added
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl added to mepivacaine (75 micrograms with 30 mL mepivacaine 1.5% with epinephrine 5 micrograms/mL)
Study: 23301674
Drug: Comprehensive eye
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive eye assessment including visual acuity, orthoptic assessment, cycloplegic autorefraction, ocular biometric variables, and ophthalmic photographs.
Study: 20860867
Drug: Enriched Supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched Supportive Therapy (Control)
Study: 10679908
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) alpha and beta (>10 U/mL), long-term exposure (144 hr)
Study: 2863380
Drug: Neuroleptic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic group (maintenance antipsychotic medication)
Study: 2863380
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drug-free)
Study: 27259552
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily antibiotic prophylaxis for 12 months
Study: 24261328
Drug: Citrate-enriched bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate-enriched bicarbonate based dialysate (CD) with 30% reduced heparin dose
Study: 24261328
Drug: Acetate-enriched bicarbonate
Normalized name: potassium acetate / potassium bicarbonate / potassium citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate-enriched bicarbonate based dialysate with standard heparin dose of ∼ 100 IU/kg (Treatment A)
Study: 22889151
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) with chemotherapy for 6 months, followed by 3 months follow-up
Study: 22889151
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without UDCA for 9 months
Study: 18826853
Drug: Standard phosphate-binder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard phosphate-binder therapy (Stx)
Study: 15796145
Drug: Protenplus (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protenplus (oral protein-energy supplement)
Study: 10542989
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with heat killed Mycobacterium vaccae
Study: 28687232
Drug: Mepolizumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (750 mg IV every 4 weeks for 6 doses)
Study: 19244174
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg injection every 4 weeks for 2 years)
Study: 19244174
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 or 40 mg daily for 2 years)
Study: 16320180
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, received no treatment
Study: 9676352
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline (500 mg) with standard breakfast
Study: 9676352
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline (500 mg) with cholecystokinin (0.3 microgram/kg)
Study: 9676352
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline (500 mg) under fasting conditions
Study: 3054451
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX, 1,000 mg/m2)
Study: 3054451
Drug: Cranial irradiation/sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial irradiation/sequential chemotherapy (RTSC)
Study: 23894039
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year trastuzumab treatment
Study: 16825698
Drug: Six-month plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-month plasma ferritin concentrations <12 microg/L in HIV-negative infants
Study: 9744143
Drug: Nisoldipine coat-core
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine coat-core (CC) 20-40 mg once daily
Study: 30825342
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (CT) intervention (resistance plus endurance training) for 20 weeks
Study: 27955850
Drug: YES IN
Normalized name: Cha Ye
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YES IN (Oral immunonutrition) administered for 8 days (3 sachets a day)
Study: 27955850
Drug: NOT IN
Normalized name: Blood group antigen associated with but not included in MNS system
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOT IN (no immunonutrition) in patients with rectal cancer
Study: 27955850
Drug: YES IN
Normalized name: Cha Ye
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YES IN (Oral immunonutrition)
Study: 24148035
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (no housing or support)
Study: 20924595
Drug: Quercetin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 150 mg
Study: 19781408
Drug: Anacetrapib, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib, 100 mg
Study: 28916311
Drug: Lenalidomide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (5 mg daily, escalated to 15 mg if tolerated)
Study: 12859326
Drug: Protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors (PIs) in the salvage regimen
Study: 12859326
Drug: >8 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: >8 months on treatment
Study: 12859326
Drug: Virological responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Virological responders (> or =1 log10 HIV-1 RNA copies/mL decrease)
Study: 11339007
Drug: Lugol's iodine
DrugBank: Potassium triiodide (DB14492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lugol's iodine treatment
Study: 8970407
Drug: Metoprolol OROS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol OROS 190 mg once daily
Study: 8970407
Drug: Metoprolol OROS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol OROS 285 mg once daily
Study: 8970407
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg 2 or 3 times daily
Study: 6373331
Drug: Topical 0.125%
Normalized name: sodium hypochlorite topical 0.125% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.125% clonidine
Study: 31537473
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (30-40 sessions, 100% oxygen, breathed at a pressure of 240-250 kPa, for 80-90 min daily)
Study: 30052208
Drug: Dexmedetomidine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.8 μg/kg/h)
Study: 30052208
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 mg/kg/h)
Study: 23672209
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection with needle electromyographic guidance (Group A, 15 patients)
Study: 23672209
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection without electromyographic guidance (Group B, 12 patients)
Study: 17666915
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg/day and Valsartan 80 mg/day (combination)
Study: 15020512
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg/day for three weeks)
Study: 12518121
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg t-PA (Group B)
Study: 12518121
Drug: No thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thrombolytic therapy (Group C)
Study: 9690729
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.d. + Amoxycillin 500 mg t.d.s. for 2 weeks (Study 1)
Study: 9690729
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. + Amoxycillin 1 g t.d.s. for 2 weeks (Study 2)
Study: 9690729
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. + Amoxycillin 1 g t.d.s. for 2 weeks (Study 3)
Study: 9690729
Drug: Omeprazole monotherapy
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole monotherapy
Study: 9690729
Drug: Amoxycillin monotherapy
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin monotherapy
Study: 2698566
Drug: Gallopamil 25
Normalized name: gallopamil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 25 mg
Study: 2698566
Drug: Gallopamil 100
Normalized name: gallopamil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 100 mg
Study: 2698566
Drug: Nifedipine (Capsule)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Capsule) 5 mg
Study: 2698566
Drug: Nifedipine (Capsule)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Capsule) 10 mg
Study: 2698566
Drug: Nifedipine (Capsule)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Capsule) 20 mg
Study: 2698566
Drug: Nifedipine (Tablet)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Tablet) 20 mg
Study: 2698566
Drug: Nifedipine (Tablet)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Tablet) 40 mg
Study: 2698566
Drug: Nifedipine (Tablet)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Tablet) 60 mg
Study: 2698566
Drug: Tiapamil 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil 300 mg
Study: 3539614
Drug: Tiapamil 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil 600 mg
Study: 1093655
Drug: Ampicillin, 500
Normalized name: Ampicillin, 500 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, 500 mg, 4 times daily for 10 days
Study: 1093655
Drug: Trimethoprim-sulfamethoxazole, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole, 4 times daily for 10 days
Study: 28560658
Drug: Pradefovir 90
Normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradefovir 90 mg
Study: 28560658
Drug: Pradefovir 120
Normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradefovir 120 mg
Study: 30576013
Drug: Vildagliptin-metformin combination
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin-metformin combination treatment
Study: 30576013
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy (standard-of-care)
Study: 23438853
Drug: Morphine (0.08mg/kg)
Normalized name: morphine 0.23 MG
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (0.08mg/kg)
Study: 14696021
Drug: Valerian 500
Normalized name: Valerian 500mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian 500 mg
Study: 14696021
Drug: Valerian 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian 1000 mg
Study: 10933133
Drug: Glibenclamide from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide from metformin/glibenclamide tablets
Study: 3921585
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (20 cm2 patch)
Study: 22623413
Drug: Oral alanyl-glutamine
Normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alanyl-glutamine (GLN) 25 g twice daily for 3 days preoperatively
Study: 17514499
Drug: MF59‐adjuvanted subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59‐adjuvanted subunit vaccine (Sub/MF59)
Study: 17383057
Drug: Conventional subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subunit vaccine (Subunit)
Study: 11436117
Drug: G‐CSF 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 6 microg/kg/day s.c.
Study: 7544174
Drug: Alpha 1-blockers
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha 1-blockers
Study: 7544174
Drug: 5 alpha-reductase
Normalized name: 5.alpha.-hydroxy laxogenin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 alpha-reductase inhibitors
Study: 2527819
Drug: ANF infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANF infusion (0.75 pmol/kg/min for 3 hours)
Study: 23648392
Drug: Need-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Need-based intervention (50g/day soy-protein-based nutritional supplement)
Study: 21710480
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml butyl‐2‐cyanoacrylate tissue glue (Glubran(®))
Study: 15587751
Drug: Calcitriol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.5 microg/day) and calcium (1000 mg/day)
Study: 15587751
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg/day) alone
Study: 11502785
Drug: GH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH administration (20 microg/kg BW)
Study: 11502785
Drug: Sex hormone
Normalized name: Sex hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone administration (hormone replacement therapy in women, testosterone enanthate in men)
Study: 11502785
Drug: GH administration,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH administration, testosterone enanthate, GH + testosterone enanthate
Study: 9426995
Drug: Ciprofloxacin 1
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1 g (CIP1)
Study: 9426995
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg b.i.d. for 1 day (CIP2)
Study: 9426995
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg b.i.d. for 3 days (D)